Univariate sensitivity analysis of the cost-effectiveness of an annual ivermectin treatment programme for onchocerciasis control. The green, blue and red lines correspond to, respectively, a pre-control endemicity of 40%, 60%, and 80% microfilarial prevalence. The baseline cost-effectiveness (with the assumptions outlined in the legend of Figure 1 ) is indicated by the thin grey horizontal line. i: Decrease in therapeutic coverage from 80% to 60%. ii: Increase in the proportion of systematic non-compliance from 0.1% to 5%. iii: Change in the discount rate from 3% ± 3% (i.e. 0-6%). iv: Inclusion of the value of the donated ivermectin tablets. v: Higher anti-macrofilarial action of ivermectin (i.e. a 30% instead of a 7% per dose reduction in microfilarial production of exposed female adult worms). vi: Different operational thresholds for treatment interruption (1.4 ± 0.5%). Thick and thin dashed lines represent the thresholds for the intervention being highly cost effective (<USD 40 per DALY averted), and cost effective (<USD 238 per DALY averted), based on World Bank criteria of cost per DALY averted (inflated to their 2012 equivalent). USD: US Dollars.
Supplementary
Highly hyperendemic 80% 85,800 4,290 58.9 98.0 § Annual biting rate (ABR): the average number of Simulium bites to which a person is exposed during a whole year. ¶ Annual transmission potential (ATP): the average number of infective larvae (L3) of Onchocerca volvulus potentially received during a whole year by a person exposed to the annual biting rate. † Both the ABR and ATP are for a proportion of vector blood meals of human origin equal to 0.3 [1] . * Arithmetic mean microfilarial load per mg of skin; note that this is different to the community microfilarial load (CMFL), which is the geometric mean microfilarial load per skin snip in those aged 20 years and above) [2] . Highly hyperendemic 0.66 0.85 * The ratio of additional costs is considered from the point of switching from annual to biannual treatment (as opposed to from the start of control).When switching from annual to biannual treatment, infection (microfilarial) prevalence was assumed to be measured at the beginning of the programmatic year (i.e. just before treatment is distributed). Pre-control microfilarial prevalence and modelling assumptions are as in the legend of Supplementary Table 2 . § The ratio of the incremental cost and the incremental number of DALYs averted by a biannual compared to annual ivermectin treatment programme (i.e. the extra cost per extra health gain). ** Highly cost-effective (<USD 40 per DALY averted), * costeffective (USD 40 to USD 238 per DALY averted) based on the World Bank cost-effectiveness thresholds (inflated to their 2012 equivalent) [3] . Pre-control microfilarial prevalence and modelling assumptions are as in the legend of Supplementary Table 2. Pre-control microfilarial prevalence and modelling assumptions are as in the legend of Supplementary Table 2 Supplementary The analysis was performed with a 50-year time horizon, discount rate of 3% applied both to costs and health benefits, therapeutic coverage of 80%, 0.1% systematic non-compliers, perennial transmission, and. Costs do not include those incurred by Merck & Co.

